Daxdilimab
Daxdilimab is an anti-ILT7 monoclonal antibody, ILT7 is a cell surface molecule specific to the pDC type of dendritic cells. Daxdilimab can be used in acute lung injury (ALI) in patients with COVID-19 infection research[1][2].
Product Specifications
CAS Number
[2245966-28-1]
Product Name Alternative
MEDI7734; VIB7734
UNSPSC
12352203
Target
SARS-CoV
Type
Inhibitory Antibodies
Related Pathways
Anti-infection
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/daxdilimab.html
Purity
99.0
Solubility
10 mM in DMSO
Smiles
[Daxdilimab]
Molecular Weight
(144.38 kDa)
References & Citations
[1]Patel S, et al. Recent updates in the clinical trials of therapeutic monoclonal antibodies targeting cytokine storm for the management of COVID-19. Heliyon. 2021 Feb;7 (2) :e06158.|[2]Retamozo S, et al. An update of targeted therapeutic options for primary Sjögren syndrome: current status and future development. Expert Opin Pharmacother. 2021 Dec;22 (17) :2359-2371.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items